ReviewDrugs2014
Omalizumab: a review of its use in patients with chronic spontaneous urticaria.
Review in Drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Interventions for chronic pruritus of unknown origin.The Cochrane database of systematic reviews · 2020Pooled it
- Trial
- Short-term omalizumab as a potential rescue therapy for alopecia areata flares during Janus kinase inhibitor maintenance.JAAD international · 2026Article
- Treating chronic urticaria refractory to H1-antihistamines in Russia: data from the AWARE study.Postepy dermatologii i alergologii · 2022Article
- Pruritus in Pregnancy.American journal of clinical dermatology · 2022Review
- Novel Targets for Drug Use in Eosinophilic Granulomatosis With Polyangiitis.Frontiers in medicine · 2021Review
- Combination therapy with omalizumab and an immune-suppressive agent for resistant chronic spontaneous rrticaria - A real-life experience.The World Allergy Organization journal · 2020Article
- Review
- Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system.ClinicoEconomics and outcomes research : CEOR · 2016Article
- Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance.Medical devices (Auckland, N.Z.) · 2015Article
- Profile of omalizumab in the treatment of chronic spontaneous urticaria.Drug design, development and therapy · 2015Review
- Omalizumab in children.Paediatric drugs · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omalizumab (Xolair(®)) is a humanized, recombinant, IgG, anti-IgE monoclonal antibody that binds to the Fc region of free IgE and prevents it from binding to its high-affinity receptor (FcεR1) on mast cells and basophils. This reduction in free IgE leads to a reduction in mast cell/basophil degranulation and the release of histamine, and to the down-regulation of FcεR1 receptors on these cells. Omalizumab does not bind to cell-bound IgE or to IgG. In well-controlled clinical trials in patients with chronic spontaneous urticaria and persistent symptoms despite background treatment with antihistamines, add-on therapy with subcutaneous omalizumab 300 mg every 4 weeks for 12 or 24 weeks significantly reduced the severity of itching, and the number and size of hives, and increased patients' health-related quality of life and the proportion of days free from angioedema compared with placebo. Subcutaneous omalizumab was generally well tolerated; the incidence and severity of adverse events in omalizumab recipients were similar to those in placebo recipients, and most adverse events were of mild or moderate severity. The only adverse events occurring more frequently with omalizumab than with placebo during treatment in a safety study were headache and upper respiratory tract infection. Thus, omalizumab is an effective and well-tolerated add-on therapy in patients with chronic spontaneous urticaria who are symptomatic despite background therapy with H1 antihistamines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.